These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 14962585)

  • 21. Spherical crystallization of drugs.
    Kovačič B; Vrečer F; Planinšek O
    Acta Pharm; 2012 Mar; 62(1):1-14. PubMed ID: 22472445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The polymorphism of statins and its effect on their physicochemical properties.
    Karaźniewicz-Łada M; Bąba K; Dolatowski F; Dobrowolska A; Rakicka M
    Polim Med; 2018; 48(2):77-82. PubMed ID: 30916495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
    Bummer PM
    Crit Rev Ther Drug Carrier Syst; 2004; 21(1):1-20. PubMed ID: 15099183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging.
    Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K
    J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical applications of cyclodextrins: basic science and product development.
    Loftsson T; Brewster ME
    J Pharm Pharmacol; 2010 Nov; 62(11):1607-21. PubMed ID: 21039545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of a solid phase reaction among excipients that accelerates drug release from a solid dispersion with aging.
    Mizuno M; Hirakura Y; Yamane I; Miyanishi H; Yokota S; Hattori M; Kajiyama A
    Int J Pharm; 2005 Nov; 305(1-2):37-51. PubMed ID: 16226411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
    Qi S; McAuley WJ; Yang Z; Tipduangta P
    Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An innovative floating gastro retentive dosage system: formulation and in vitro evaluation.
    Sauzet C; Claeys-Bruno M; Nicolas M; Kister J; Piccerelle P; Prinderre P
    Int J Pharm; 2009 Aug; 378(1-2):23-9. PubMed ID: 19465095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral lipid-based formulations.
    Hauss DJ
    Adv Drug Deliv Rev; 2007 Jul; 59(7):667-76. PubMed ID: 17618704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. smartPearls - Novel physically stable amorphous delivery system for poorly soluble dermal actives.
    Müller RH; Hespeler D; Jin N; Pyo SM
    Int J Pharm; 2019 Jan; 555():314-321. PubMed ID: 30439490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of excipient interactions on drug bioavailability from solid dosage forms.
    Panakanti R; Narang AS
    Pharm Res; 2012 Oct; 29(10):2639-59. PubMed ID: 22610283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E
    Ann Pharm Fr; 2002 May; 60(3):161-76. PubMed ID: 12050595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
    Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
    Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
    Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
    Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.